CSIMarket
 


Uniqure N v   (QURE)
Other Ticker:  
 
 

QURE's Revenue Growth by Quarter and Year

Uniqure N V 's Revenue results by quarter and year




QURE Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 102.75 57.69 1.79
III Quarter September 1.41 1.45 1.99 1.54
II Quarter June 2.42 0.50 463.87 0.10
I Quarter March 5.33 1.79 0.45 2.63
FY   9.16 106.49 524.00 6.06



QURE Revenue third quarter 2023 Y/Y Growth Comment
Uniqure N V reported decrease in Revenue in the third quarter 2023 by -2.97% to $ 1.41 millions, from the same quarter in 2022.
The decrease in the third quarter 2023 Uniqure N V 's Revenue compares unfavorably to the Company's average Revenue doubling of 1480.56%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 158 other companies have achieved higher Revenue growth. While Uniqure N V ' s Revenue decline of -2.97% ranks overall at the positon no. 2349 in the third quarter 2023.




QURE Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - 78.11 % 3122.91 % 70.48 %
III Quarter September -2.97 % -27.14 % 29.22 % -37.65 %
II Quarter June 384 % -99.89 % 463770 % -91.23 %
I Quarter March 197.77 % 297.78 % -82.89 % 9.58 %
FY   - -79.68 % 8546.86 % -14.16 %

Financial Statements
Uniqure N V 's third quarter 2023 Revenue $ 1.41 millions QURE's Income Statement
Uniqure N V 's third quarter 2022 Revenue $ 1.45 millions Quarterly QURE's Income Statement
New: More QURE's historic Revenue Growth >>


QURE Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - 6986.21 % 2798.99 % 16.23 %
III Quarter September -41.86 % 190 % -99.57 % 1440 %
II Quarter June -54.6 % -72.07 % 102982.22 % -96.2 %
I Quarter March -94.81 % -96.9 % -74.86 % 150.48 %
FY (Year on Year)   - -79.68 % 8546.86 % -14.16 %




Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #159
Healthcare Sector #413
Overall #2349

Revenue Y/Y Growth Statistics
High Average Low
30119.41 % 1480.56 % -99.89 %
(Jun 30 2021)   (Jun 30 2022)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #159
Healthcare Sector #413
Overall #2349
Revenue Y/Y Growth Statistics
High Average Low
30119.41 % 1480.56 % -99.89 %
(Jun 30 2021)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Uniqure N V 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
102073.57 % 4710.91 % -99.57 %
(Jun 30 2021)  


QURE's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Uniqure N V reported fall in Revenue from the previous quarter by -41.86% to $ 1.41 millions, from $ 2.42 millions released a quarter before.

Even periodic influence were not able to recover the III. Quarter for the Uniqure N v , Atharv Nair, Major Pharmaceutical Preparations industry insider said, he voiced some skepticism for the QURE's direction and mentioned that average sequential Revenue growth is at 4710.91% for QURE.

Within Major Pharmaceutical Preparations industry 210 other companies have achieved higher Revenue quarter on quarter growth. While Uniqure N V 's Revenue growth quarter on quarter, overall rank is 3504.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #211
Healthcare Sector #563
Overall #3504
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #211
Healthcare Sector #563
Overall #3504
Revenue Q/Q Growth Statistics
High Average Low
102073.57 % 4710.91 % -99.57 %
(Jun 30 2021)  


QURE's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Uniqure N V realized fall in Revenue from the previous quarter by -41.86% to $ 1.41 millions, from $ 2.42 millions declared in the previous quarter.

Those periodic influence which usually elevate III. Quarter 2023 Revenue, were not able to salvage the III. Quarter for the Uniqure N v , Atharv Nair, Major Pharmaceutical Preparations industry insider pointed out and continued that average quarter on quarter Revenue growth is at 4710.91% for QURE.

Within Major Pharmaceutical Preparations industry 210 other companies have achieved higher Revenue quarter on quarter growth. While Uniqure N V 's Revenue growth quarter on quarter, overall rank is 3504.


Uniqure N V 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 111.90 $ 111.94 $ 110.02 $ 106.48 $ 61.43
Y / Y Revenue Growth (TTM) 82.16 % 80.64 % -79.06 % -79.68 % -86.88 %
Year on Year Revenue Growth Overall Ranking # 1732 # 707 # 6 # 4 # 928
Seqeuential Revenue Change (TTM) -0.04 % 1.75 % 3.32 % 73.34 % -0.87 %
Seq. Revenue Growth (TTM) Overall Ranking # 1995 # 3689 # 2012 # 1160 # 783




Cumulative Revenue growth Comment
Although Uniqure N V 's Annual Revenue growth year on year were below company's average 2091.78% , Revenue announced in the Sep 30 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 82.16% year on year, from 80.64% in Jun 30 2023.

In the Healthcare sector 214 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 707 to 1732.

Revenue TTM Q/Q Growth Statistics
High Average Low
13432.72 %
2091.78 %
-86.88 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 215
Overall # 1732

Revenue TTM Y/Y Growth Statistics
High Average Low
13432.72 %
2091.78 %
-86.88 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 334
S&P 500 # 1995
Cumulative Revenue growth Comment
Although Uniqure N V 's Annual Revenue growth year on year were below company's average 2091.78% , Revenue announced in the Sep 30 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 82.16% year on year, from 80.64% in Jun 30 2023.

In the Healthcare sector 214 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 707 to 1732.

Revenue TTM Q/Q Growth Statistics
High Average Low
13432.72 %
2091.78 %
-86.88 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 215
Overall # 1732

Revenue TTM Y/Y Growth Statistics
High Average Low
13432.72 %
2091.78 %
-86.88 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 334
S&P 500 # 1995




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
QURE's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for QURE's Competitors
Revenue Growth for Uniqure N V 's Suppliers
Revenue Growth for QURE's Customers

You may also want to know
QURE's Annual Growth Rates QURE's Profitability Ratios QURE's Asset Turnover Ratio QURE's Dividend Growth
QURE's Roe QURE's Valuation Ratios QURE's Financial Strength Ratios QURE's Dividend Payout Ratio
QURE's Roa QURE's Inventory Turnover Ratio QURE's Growth Rates QURE's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Procyon Corporation-0.22%$ -0.221 millions
Amedisys Inc -0.31%$ -0.314 millions
Karyopharm Therapeutics Inc -0.38%$ -0.376 millions
Establishment Labs Holdings Inc -0.50%$ -0.505 millions
Opko Health Inc -0.64%$ -0.639 millions
Integra Lifesciences Holdings Corp-0.72%$ -0.719 millions
Healthcare Services Group Inc -0.75%$ -0.748 millions
Phibro Animal Health Corporation-0.77%$ -0.772 millions
Bellicum Pharmaceuticals Inc -0.89%$ -0.890 millions
Prestige Consumer Healthcare Inc -1.12%$ -1.125 millions
Sharecare Inc -1.13%$ -1.127 millions
Lifevantage Corp-1.14%$ -1.140 millions
Organon and Co -1.17%$ -1.171 millions
Optinose Inc -1.27%$ -1.270 millions
Baxter International Inc -1.72%$ -1.723 millions
Puma Biotechnology Inc -1.73%$ -1.727 millions
Blueprint Medicines Corporation-1.76%$ -1.763 millions
Standard Biotools Inc -1.92%$ -1.918 millions
Pacira Biosciences inc -2.11%$ -2.114 millions
Bristol myers Squibb Company-2.25%$ -2.246 millions
Aurinia Pharmaceuticals Inc -2.27%$ -2.266 millions
Abbott Laboratories-2.56%$ -2.565 millions
Enhabit Inc -2.79%$ -2.785 millions
Novocure Limited-2.81%$ -2.807 millions
Uniqure N v -2.90%$ -2.899 millions
Vaso Corporation-2.92%$ -2.925 millions
Scientific Industries Inc -3.16%$ -3.165 millions
Akumin Inc -3.21%$ -3.205 millions
Syros Pharmaceuticals Inc -3.32%$ -3.315 millions
Viatris Inc -3.34%$ -3.342 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com